63 results about "Hepatitis b e antigen" patented technology

The invention relates to a diagnosing reagent for hepatitis B, disclosing detection grains for e antigens of the hepatitis B virus, which are of the luminous grains coated by anti-HBE antibodies. The invention also discloses preparation and application for the detection grains for e antigens of the hepatitis B virus; moreover, the invention further discloses an outside-body diagnosis reagent box for detecting e antigens of the hepatitis B in a blood serum sample of human beings as well as a method for utilizing the light excitation chemiluminescence principle to quantitatively and qualitatively detect e antigens of the hepatitis B virus. The reagent box of the invention can be jointly used to diagnose the individual acute or chronic hepatitis B together with other blood serums and clinic information, and screen the hepatitis B for women in the perinatal period so as to judge the risk of newborn babies contaminating the hepatitis B.

The invention relates to the preparation of brominated flavanonollignan and an application in medicines for treating viral hepatitis B, in particular to a B cyclo-dioxane flavanonollignan compound and a preparation method thereof as well as the application of the compound or pharmaceutically acceptable salts thereof in the preparation of medicines for eliminating hepatitis B surface antigens (HBsAg) and hepatitis B e antigens (HBeAg) and medicines for inhibiting HBV DNA replication. The compound has obvious activity of inhibiting HBsAg and HBeAg, and the intensities of the compound for eliminating HBsAg and HBeAg under the concentration of 20 microgram/millimeter are respectively 2.1 times and 1.2 times larger than the corresponding activity of a positive control medicine alpha-interferon; meanwhile, the compound displays high inhibition ratio more than 57% on HBV DNA at the concentration. The results show that the favonolignan or pharmaceutically acceptable salts thereof can be expected to be used for preparing non-nucleoside type medicines for eliminating HBsAg and HBeAg, inhibiting HBV DNA replication and treating HBV infected diseases.

The invention relates to application of ring A coupling flavonolignan in preparing medicaments for treating viral hepatitis B, in particular to application of a compound of the formula (1) or a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away HBsAg (Hepatitis B Surface Antigen) and HBeAg (Hepatitis B e Antigen) and suppressing the HBV (Hepatitis B Virus) DNA replication. The intensities of the flavonolignan for clearing away the HBsAg and the HBeAg are respectively 29.4 percent and 29.1 percent in the presence of a concentration of 20 micrograms/milliliter, which is respectively 1.8 times and 1.7 times of the corresponding activity of a positive control medicament (10,000 units/milliliter of alpha-interferon). What is even more exciting is that in the presence of the concentration, the suppression rate of the flavonolignan to the HBV DNA is higher than 83 percent, which is higher than that of Lamivudine which is a positive control and is 2.2 times of that of the alpha-interferon to the HBV DNA. Accordingly, the flavonolignan and the pharmaceutically acceptable salt thereof are indicated to be capable of being expected to be used for preparing non-nucleoside medicaments for clearing away the HBsAg and the HBeAg, suppressing the HBV DNA replication and treating HBV infection diseases.

The invention relates to a use of lignanoid containing benzyloxy flavones in the preparation of drugs for treating viral hepatitis B, in particular to the use of a compound as shown in formula (1) or pharmaceutical salts thereof in the preparation of the drugs for eliminating hepatitis B virus surface antigen and hepatitis B e antigen and the drugs for suppressing HBV DNA replication, and the strength of eliminating HBsAg of flavonol lignanoid under the concentration of 20 mu g/ml is 50.8%, which is 3.2 times of the corresponding activity of a positive control drug; the activity of eliminating the HBeAg under the same concentration is equivalent to 10000 units/ml of alpha-interferon; simultaneously, the flavonol lignanoid shows nearly 60% of suppression rate to HBV DNA under the concentration, which is 1.6 times of the corresponding suppression rate of the alpha-interferon. The results show that the lignanoid containing the flavones or the pharmaceutical salts thereof are expected to be used for preparing the non-nucleoside drugs for eliminating the HBsAg and the HBeAg, suppressing the HBV DNA replication and treating hepatitis B virus infection diseases.

The invention relates to application of ring B ethyoxyl silybin in preparing medicaments for treating viral hepatitis B, in particular to application of ring B ethyoxyl substituted silybin ester or a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away HBsAG (Hepatitis B Surface Antigen) and HBeAg (Hepatitis B e Antigen) and suppressing the HBV (Hepatitis B Virus) DNA replication. The compound has strong activity on suppressing the HBsAG and the HBeAg, and in the presence of a concentration of 20 micrograms/milliliter, the intensities for clearing the HBsAg and the HBeAg are respectively 64.6 percent and 44.8 percent which are 4.0 times and 2.7 times of that of alpha-interferon which is a positive control medicament. In the presence of the concentration, the suppression rate of the compound on the HBV DNA is 58.1 percent which is 1.5 times of the corresponding activity of the alpha-interferon. Accordingly, the flavonolignan or the pharmaceutically acceptable salt thereof are indicated to simultaneously have strong efficacy on suppressing the HBsAg, the HBeAg and the HBV DNA and can be expected to be used for preparing non-nucleoside medicaments for treating HBV infection diseases.

The invention relates to application of B/E bi-methoxy silybin in preparing medicaments for treating viral hepatitis B, in particular to application of silybin ester substituted by the methoxy on the ring B and the ring E or a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away HBsAg (Hepatitis B Surface Antigen) and HBeAg (Hepatitis B e Antigen) and suppressing the HBV (Hepatitis B Virus) DNA replication. The B/E bi-methoxy silybin has strong activity on suppressing the HBsAg and the HBeAg, and in the presence of a concentration of 20 micrograms/milliliter, the intensities for clearing away the HBsAg and the HBeAg are respectively 43.9 percent and 43.7 percent which are 2.7 times and 2.6 times of that of alpha-interferon which is a positive control medicament. In the presence of the concentration, the suppression ratio on the HBV DNA is 68.6 percent, and the suppression activity is 1.8 times of that of the alpha-interferon. Accordingly, the flavone lignan or the pharmaceutically acceptable salt thereof are indicated to simultaneously have the effects of strongly suppressing the HBsAG, the HBeAg and the HBV DNA and can be expected to be used for preparing the non-nucleoside medicaments for treating HBV infection diseases.

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of 20 microgram/milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.

The invention belongs to the immunoassay technical field and relates to a hepatitis B e antibody magnetic particle chemiluminescent immunoassay kit. The kit of the invention comprises a mixed liquor of hepatitis B e antibody coated with magnetic particle and horse radish peroxidase-labeled hepatitis B e antibody, hepatitis B e antigen, hepatitis B e antibody calibrator, chemiluminescence substrate solution, concentrated cleaning solution and reaction tubes. The invention can be used to test the content of hepatitis B e antibody in human serum and has the advantages of simple and fast operation, good repetitiveness and the like.

The invention relates to a magnetic immunochromatographic test strip for detecting hepatitis B e antigen in blood and a preparation method thereof. The magnetic immunochromatographic test strip introduces the magnetic micro-particle immunochromatographic technology into the hepatitis B e antigen detection, and the test strip is assembled by sequentially mutually sticking a coating film, a magnetic particle pad combined with hepatitis B e antibody, a sample pad and a water-absorbing pad on a substrate in a staggered manner and then covering a transparent plastic sealing film on the upper layer. A hepatitis B e antigen detection line and a quality control line are pre-coated on the coating film. The magnetic immunochromatographic test strip has the advantages of simple operation, high sensitivity, good specificity and the like.

The invention belongs to the technical field of immunoassay and biosensing, and provides a preparation method of an electrochemical immunosensor of PdCu nanowire functionalized porous graphene. The PdCu nanowire functionalized porous graphene is used as an electrochemical signal amplification platform to construct a marker-free electrochemical immunosensor, so that quantitative detection of hepatitis B e antigen is achieved, the preparation method of the electrochemical immunosensor of the PdCu nanowire functionalized porous graphene has the advantages of high specificity, high sensitivity, low detection limit and the like, and has important scientific significance and application value for detection of hepatitis B.

The invention discloses a pharmaceutical composition for treating hepatopathy, which is a preparation prepared by the following active pharmaceutical ingredients in portions by weight: 3-5 portions of black nightshade herb, 2-3 portions of common scouring rush herb, 4-8 portions of wild buckwheat rhizome, 3-5 portions of Indian kalimeris herb, 2-5 portions of zedoary, 3-5 portions of carrageen, 3-5 portions of Indian rorippa herb, 3-5 portions of lightyellow sophora root, 3-5 portions of virgate wormwood herb, 3-8 portions of coix seed and 3-5 portions of sinkiang arnebia root. The pharmaceutical composition can effectively inhibit virus replication, convert hepatitis B e-antigen and hepatitis B virus (DNA: deoxyribonucleic acid) gene polymerase to be negative within 40 weeks, effectively treat hepatitis B, further reduce the liver fibrosis level, improve the organic disorder in liver and spleen, increase the seralbumin, quickly reduce the liver functional seroenzyme, restore liver functions, have a good effect of protecting the liver, and effectively treat viral hepatitis and cirrhosis; and the pharmaceutical composition particularly has significant treatment effect for the hepatitis B and the cirrhosis after various types of the hepatitis.

The invention relates to application of p-bromo-cinnamyl silybin in preparing a medicament for treating viral hepatitis B, in particular to application of 23-site p-bromo-cinnamyl base substituted silybin ester or pharmaceutically acceptable salts thereof in preparing a medicament for removing surface antigen of a hepatitis B virus and a hepatitis B e antigen and inhibiting HBVDNA replication. The medicament has obvious HBsAg inhibiting and HBeAg inhibiting activity, and the strengths for removing HBsAg and HBeAg at the concentration of 20 microgrammes/ml are respectively 98.9 percent and 90.9 percent and respectively exceed the strength of a positive contrast medicament alpha-interferon by 6.1 times and 5.4 times; and meanwhile, the medicament displays about 60 percent of inhibition ratio on HBVDNA at the concentration and is 157 percent higher than the alpha-interferon. It is indicated that the favonolignan or the pharmaceutically acceptable salts thereof can be expected for preparing a non-nucleoside medicament for removing HBsAg and HBeAg, inhibiting HBVDNA replication and treating a hepatitis B virus infection disease.

The invention relates to an application of isoflavonoids compounds, i.e., tectoridin, iridin, irisflorentin, tectorigenin or irigenin, separated from the belamcanda chinensis of an iridaceae belamcanda plant to preparation of drugs or health-care foods for preventing and treating hepatitis, relating to the technical field of natural pharmaceutical chemistry and medicines. In the invention, HBsAg (Hepatitis B Surface Antigen) and HBeAg(Hepatitis B e Antigen) resistance experiments are carried out by adopting detection reagents of an HBsAg diagnostic reagent kit and an HBeAg diagnostic reagent kit; and an experimental result discovers that all the tectoridin, the iridin, the irisflorentin, the tectorigenin and the irigenin have an obvious hepatitis B virus resistant action, thus the tectoridin, the iridin, the irisflorentin, the tectorigenin and the irigenin can be used for preparing the drugs or health-care foods for preventing and treating hepatitis viruses.

The invention provides a hepatitis B virus e antigen immune evasion detection gene chip and a kit, belonging to the gene chip technique field of clinical detection, and comprising: a gene chip of a specific DNA probe which detects hepatitis B virus e antigen immune evasion and is fixed on a solid phase carrier as well as a matched reagent; the matched reagent includes a treating fluid for treating serum samples, an amplifying solution for amplifying and labeling the treated samples, a hybridization solution in hybridization reaction with a micro-array, a cleaning solution, an enzyme-labeled working solution and a detection liquid; and the matched reagent and the hepatitis B virus e antigen immune evasion detection gene chip are used jointly in the detection process of the serum samples. The chip and the kit can detect the hepatitis B virus e antigen immune evasion, and avoid the clinical hepatitis B virus e antigen leak detection, thereby being favorable for judging the infectivity and conditions after curing of hepatitis B patients.

The present invention provides regulation of expression of toll-like receptors by the hepatitis B (HBV) pre-core protein, or its extracellular expression product the hepatitis B E antigen (HbeAg). Compounds regulating such expression have use in the treatment and prophylaxis of HBV infection in animal. The invention also provides methods for diagnosing HBV and agents useful in diagnostic protocols. The present invention further contemplates methods for monitoring disease states in humans and other animal species, including animal models, and providing an indication of the subject for infection by HBV, or development of other diseased states.

The present invention discloses a hepatitis B virus e antigen detection kit, which comprises a hepatitis B e antigen calibration substance, an anti-HBe monoclonal antibody coated plate, europium labeled anti-HBe monoclonal antibody, an assay buffer liquid, a fluorescence enhanced liquid and a concentrated washing liquid. The present invention further discloses a preparation method of the kit, and a method for detecting hepatitis B virus e antigen by using the kit. According to the present invention, the kit has advantages of high detection sensitivity, good specificity, simple operation, no pollution, and low cost, can be used for quantitative detection of the HBeAg content in human serum/plasma, and provides precise reference for the clinical hepatitis B individualized management treatment program.

The invention relates to application of benzyl-containing flavonoid lignan in preparation of a medicament for treating hepatitis B, in particular to application of flavonoid lignan and pharmaceutically-acceptable salt thereof in preparation of the medicament for eliminating hepatitis B e antigen, inhibiting hepatitis B virus desoxyribonucleic acid (HBV DNA) replication and treating viral hepatitis B. The flavonoid lignan can inhibit the activity of hepatitis B virus e antigen (HBeAg); the inhibition intensity of the flavonoid lignan under low concentration of 20 micrograms per milliliter is much higher than that of a positive control front-line medicament lamivudine and an interferon; and the compound with the concentration of 20 micrograms per milliliter displays an inhabitation ratio over 50 percent on the HBV DNA, so that the application of the flavonoid lignan in preparation of the medicament for eliminating the hepatitis B e antigen and the medicament for inhibiting the HBV DNA replication and treating hepatitis B viral diseases can be anticipated.

Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.

The invention relates to application of flavanonol lignanoid in preparing an antiviral hepatitis B medicine, in particular to application of angle flavanolignan or pharmaceutically acceptable salts thereof in preparing a medicine which can be used for eliminating hepatitis B e antigen HBeAg, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases. The flavanolignan has a certain HBeVg activity inhibition, the HBeAg elimination intensity of the flavanolignan is higher than that of a positive control first-line medicine as lamivudine in light concentration and is equivalent to that of alpha-interferon of 1000 unit/ml, and meanwhile, under the concentration of 20 microgram/ml, the flavanolignan displays an inhibition ratio which is larger than 45 percent for HBV DNA. The pharmacodynamics result indicates the application of the flavanolignan or the pharmaceutically acceptable salts thereof in preparing the medicine as expected for eliminating hepatitis B e antigen, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases.